Mortality rates of human metapneumovirus and respiratory syncytial virus lower respiratory tract infections in hematopoietic cell transplantation recipients.
about
Preventing stem cell transplantation-associated viral infections using T-cell therapyAntiviral T-cell therapyChallenges and opportunities in developing respiratory syncytial virus therapeuticsHuman rhinovirus detection in the lower respiratory tract of hematopoietic cell transplant recipients: association with mortality.Prophylaxis with a respiratory syncytial virus (RSV) anti-G protein monoclonal antibody shifts the adaptive immune response to RSV rA2-line19F infection from Th2 to Th1 in BALB/c mice.Idiopathic pneumonia syndrome after hematopoietic cell transplantation: evidence of occult infectious etiologiesLong-Term Shedding of Influenza Virus, Parainfluenza Virus, Respiratory Syncytial Virus and Nosocomial Epidemiology in Patients with Hematological DisordersSafety and immunogenicity of novel respiratory syncytial virus (RSV) vaccines based on the RSV viral proteins F, N and M2-1 encoded by simian adenovirus (PanAd3-RSV) and MVA (MVA-RSV); protocol for an open-label, dose-escalation, single-centre, phasChimpanzee adenovirus- and MVA-vectored respiratory syncytial virus vaccine is safe and immunogenic in adults.How I treat respiratory viral infections in the setting of intensive chemotherapy or hematopoietic cell transplantationHuman Metapneumovirus Infections Following Hematopoietic Cell Transplantation: Factors Associated With Disease Progression.Laboratory Diagnosis of Infections in Cancer Patients: Challenges and Opportunities.Cytomegalovirus (CMV) DNA Quantitation in Bronchoalveolar Lavage Fluid From Hematopoietic Stem Cell Transplant Recipients With CMV Pneumonia.Prolonged Shedding of Human Coronavirus in Hematopoietic Cell Transplant Recipients: Risk Factors and Viral Genome Evolution.Human metapneumovirus infections in hematopoietic cell transplant recipients and hematologic malignancy patients: A systematic review.Modulation of Host Immunity by the Human Metapneumovirus.Clinical Significance of Human Coronavirus in Bronchoalveolar Lavage Samples From Hematopoietic Cell Transplant Recipients and Patients With Hematologic Malignancies.Corticosteroid use as adjunct therapy for respiratory syncytial virus infection in adult allogeneic stem cell transplant recipients.Human metapneumovirus in lung transplant recipients: characteristics and outcomes.BCSH/BSBMT/UK clinical virology network guideline: diagnosis and management of common respiratory viral infections in patients undergoing treatment for haematological malignancies or stem cell transplantation.Incidence and predictors of respiratory viral infections by multiplex PCR in allogeneic hematopoietic cell transplant recipients 50 years and older including geriatric assessment.Management of Acute Respiratory Failure in Patients With Hematological Malignancy.Serious outbreak of human metapneumovirus in patients with hematologic malignancies.Respiratory Syncytial Virus in Hematopoietic Stem Cell Transplantation and Solid-Organ Transplantation.Oxygen-free days in hematopoietic cell transplant recipients with respiratory syncytial virus.Immunologic Profiling of Human Metapneumovirus for the Development of Targeted Immunotherapy.A Multicenter Consortium to Define the Epidemiology and Outcomes of Inpatient Respiratory Viral Infections in Pediatric Hematopoietic Stem Cell Transplant Recipients.
P2860
Q26801365-5EF1B0AC-39E7-4BCF-84AD-2AE2AA132A40Q27028006-6E1CAAAC-9024-4AB8-B6B9-B1937896B19FQ30300567-61A6B174-F08C-4993-8DFA-F541403ACD8CQ33746756-8D691246-B25D-443A-AAAD-DFC90CFCA96DQ34262180-E75E7404-23FD-4EE1-9753-EEA38DF00A04Q35724040-4F50A3B7-9896-4377-B1D5-576CE5D66BDAQ35920582-7CECA86D-64BB-4720-A964-D0E1EC3F6547Q36258838-CD7BA577-2052-4F52-B59C-D5FBEB7B0878Q36347381-E48EC45C-887F-4F3E-B809-4A32095FD3E0Q36965855-D41C68B1-FFB6-4A82-89E6-5426D7AFDC13Q37055033-78961C36-A5FB-4DF4-9FE5-3332FBD7A519Q37363377-D325E13D-3DDC-4E71-8C19-6D2E11689488Q38376028-B419E7DC-E372-44A3-9476-BBA35DDCA9BCQ38609821-CE455CA9-8F9C-4987-9616-C49214F37F3EQ38853701-0175C676-EF07-4AE8-A661-7C5DB2027232Q38896046-762DFF5C-6C90-45CB-BA94-03212D05DE2FQ39193577-4456EC61-E0DE-4F4A-86B4-FF23310F131AQ39973043-49520E07-78FC-4242-B13F-D465E3132FF4Q40622991-1DD80804-EA6B-4D68-8DB9-F69F667F247FQ40721939-2F3C9F11-2FE3-43EA-9009-23ED9304A1B2Q40859434-B445CA55-6597-4FE7-BA6E-A3BEB2D3EBEBQ41047392-AA8AAD34-37A5-4550-A395-2DBEA1CC613FQ41133863-10647B64-38FF-409B-A6C9-BEB7607FD78CQ41166298-6343E357-E534-451D-B7CB-4B30468E6E08Q41927841-FA1198A0-CB1C-4506-B9D1-18B0EA54ADC0Q41932831-3107247F-139A-436E-BEC8-52401731D817Q47589771-A931BF4F-6652-4286-AD1D-A6F040D89586
P2860
Mortality rates of human metapneumovirus and respiratory syncytial virus lower respiratory tract infections in hematopoietic cell transplantation recipients.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 13 May 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Mortality rates of human metap ...... ll transplantation recipients.
@en
Mortality rates of human metap ...... ll transplantation recipients.
@nl
type
label
Mortality rates of human metap ...... ll transplantation recipients.
@en
Mortality rates of human metap ...... ll transplantation recipients.
@nl
prefLabel
Mortality rates of human metap ...... ll transplantation recipients.
@en
Mortality rates of human metap ...... ll transplantation recipients.
@nl
P2093
P2860
P50
P1476
Mortality rates of human metap ...... ll transplantation recipients.
@en
P2093
Christian Renaud
Jane Kuypers
Janet A Englund
Sachiko Seo
P2860
P304
P356
10.1016/J.BBMT.2013.05.005
P577
2013-05-13T00:00:00Z